In the framework of MetaboMARKER we have identified a compendium of metabolic genes that coordinately inform about the aggressiveness of prostate cancer. Stemming from this observation, MetaboMarker has allowed us to refine the technical genetic signature properties, build on new applications that emanate from our gene list and evaluate the potential impact on the market and the best strategy to bring it to the patient.
During the course of the proposal, we have performed a deep market analysis and have evaluated the best technology that could support the clinical application of the results obtained. We believe that this signature can provide unique clinical information about the aggressive features of prostate cancer, and, in turn, it could aid in the refinement of clinical guidelines for the treatment of this disease.
